MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox in Canada
12 September 2016
MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
(Pickering, Canada and Victoria, Australia, 12 September 2016) Medical Developments International Limited (MDI) (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
For details relating to the full ASX release, please click on the following link: MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox in Canada